SCHEDULE: Stonepine Capital Discloses 9.9% Stake in CNS Pharma

Stonepine Capital Management has filed a Schedule 13G reporting a 9.9% beneficial ownership stake in CNS Pharmaceuticals, Inc. consisting of common stock and warrants.

Summary

• Stonepine Capital Management, LLC, along with its affiliates and Jon M. Plexico, reported a 9.9% beneficial ownership interest in CNS Pharmaceuticals, Inc.
• The holdings consist of 21,738 shares of common stock and warrants to purchase 1,304,348 shares of common stock.
• The ownership percentage is subject to a 9.99% beneficial ownership limitation.
• The calculation is based on 1,461,449 shares of common stock outstanding as of May 13, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing institutional interest without indicating a change in strategic direction or control.

Positives

• Institutional investor maintains a significant 9.9% stake, signaling potential long-term interest in the issuer.

Negatives

• The majority of the reported beneficial ownership (1,304,348 shares) is derived from warrants rather than direct common stock ownership.
• The reporting persons have no sole voting or dispositive power, holding only shared power.

Risks

• The investment is subject to a 9.99% beneficial ownership limitation, which restricts the ability of the reporting person to exercise warrants if it would exceed this threshold.
• The issuer's low share count (1,461,449) suggests high volatility and potential liquidity risks for investors.

Future Outlook

The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional disclosure requirements for small-cap biotechnology firms, where warrant-heavy positions are common to manage capital structure and dilution.

Comparison to Industry Standards

• The 9.9% ownership threshold is a common strategic ceiling for institutional investors in small-cap biotech to avoid triggering more stringent regulatory reporting requirements associated with 10%+ ownership.

Stakeholder Impact

• Shareholders should note the significant warrant position, which may lead to future dilution if exercised.

Next Steps

• The reporting persons will continue to monitor their investment in CNS Pharmaceuticals.

Key Dates

Keywords

CNS Pharmaceuticals, Stonepine Capital, Schedule 13G, Beneficial Ownership, Biotech, Warrants